You are here: Industry Insights > Novartis

News List

M&As this week: Intermediate Capital Group, Novartis pharmatimes
June 13, 2018
Intermediate Capital Group has completed the acquisition of SuanFarma from ProA Capital, a private equity firm based in Spain.
Amgen/Novartis migraine med gets CHMP nod pharmafile
June 07, 2018
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally a precursor to an approval by the EMA.
Amgen/Novartis migraine med gets CHMP nod pharmafile
June 07, 2018
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally a precursor to an approval by the EMA.
Novartis’ US Oncology head makes leap to become biotech CEO pharmafile
June 07, 2018
The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill Hinshaw, former Executive Vice President of US Oncology at Novartis, who exits the company to head to Axcella Health, becoming i
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it? fiercepharma
June 04, 2018
Novartis rolled out positive first-line metastatic Kisqali results at annual ASCO meeting in Chicago.
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer worldpharmanews
May 23, 2018
Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association (EHA)
Aurobindo launches $1.6 billion bid to buy Novartis generics unit biospectrumasia
May 08, 2018
Novartis is considering a sale of its dermatology generics drugs business under the Sandoz brand
Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report fiercepharma
May 08, 2018
As Novartis tries to shed some of its Sandoz offerings in the U.S. under intense pricing pressure, the drugmaker may have found a buyer for a generic dermatology business. India's Aurobindo has submitted a $1.6 billion offer for the unit, according to Liv
Novartis becomes first to gain second CAR-T indication pharmafile
May 04, 2018
Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of treatment
Novartis' biosimilar rituximab delayed in US pharmatimes
May 04, 2018
Novartis' Sandoz division announced today that the US FDA has issued a complete response letter regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab, meaning that approval of the drug has been delayed in the country.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page